Application of imiquimod and resiquimod in dermatology.
- Author:
Ke-Jian XU
1
;
Yue-Hua LIU
Author Information
1. Department of Dermatology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. axukejian@tom.com
- Publication Type:Journal Article
- MeSH:
Adjuvants, Immunologic;
therapeutic use;
Aminoquinolines;
therapeutic use;
Antineoplastic Agents;
therapeutic use;
Condylomata Acuminata;
drug therapy;
Humans;
Imidazoles;
therapeutic use;
Skin Neoplasms;
drug therapy
- From:
Acta Academiae Medicinae Sinicae
2006;28(3):445-447
- CountryChina
- Language:Chinese
-
Abstract:
Imiquimod (R-837) and Resiquimod (R-838), two novel small-molecular-weight immune response modifiers, have similar structure. They have anti-virus and anti-tumor activities and can be used as B lymphocyte activators and adjuvants. They are widely used in dermatology to treat virus dermatoses and cutaneous benign or malignant tumors.
